SEC Company Response from PURPLE BIOTECH LTD. (PPBT) (CIK 0001614744) (PPBT) — Jun 28, 2016
PURPLE BIOTECH LTD. (PPBT) (CIK 0001614744)
Date: June 28, 2016 · CIK: 0001614744 · Accession: 0001144204-16-110152
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-211477
Letter
Re: KITOV PHARMACEUTICALS HOLDINGS LTD.
June 28, 2016
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Registration Statement on Form F-1 (Registration No. 333-211477)
Concurrence in Acceleration Request
Ladies and Gentlemen:
H.C. Wainwright & Co., LLC (“Wainwright”), as placement agent for the referenced offering, hereby concurs in the request by Kitov Pharmaceuticals Holdings Ltd. that the effective date of the above-referenced registration statement be accelerated to 4:30 p.m. (Eastern Time), or as soon as practicable thereafter, on June 28, 2016, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act in connection with this offering.
Very truly yours,
H.C. WAINWRIGHT & CO., LLC
Show Raw Text
CORRESP
1
filename1.htm
June 28, 2016
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Re: KITOV PHARMACEUTICALS HOLDINGS LTD.
Registration
Statement on Form F-1 (Registration No. 333-211477)
Concurrence
in Acceleration Request
Ladies and Gentlemen:
H.C. Wainwright &
Co., LLC (“Wainwright”), as placement agent for the referenced offering, hereby concurs in the request by Kitov
Pharmaceuticals Holdings Ltd. that the effective date of the above-referenced registration statement be accelerated to 4:30 p.m.
(Eastern Time), or as soon as practicable thereafter, on June 28, 2016, pursuant to Rule 461 under the Securities Act. Wainwright
affirms that it is aware of its obligations under the Securities Act in connection with this offering.
Very truly yours,
H.C. WAINWRIGHT & CO., LLC
By:
/s/ Mark W. Viklund
Name: Mark W. Viklund
Title: Chief Executive Officer